A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Pexidartinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Plexxikon
- 26 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2014 Planned End Date changed from 1 Sep 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 28 Aug 2014 Planned primary completion date changed to 1 May 2013 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History